Doctors have for the first time in the United States tested a powerful gene-editing technique in people with cancer.

In the earnings call yesterday after the close, Nektar Therapeutics (NASDAQ:NKTR) President & CEO Howard Robin mentioned a "softening in response rates" in the Phase 1/2 PIVOT-02 study evaluating NKTR-214 (bempegaldesleukin)

The FDA approves Incyte's Jakafi (ruxolitinib) for the treatment of steroid-refractory acute graft-versus-host disease (GvHD)

Regeneron Pharmaceuticals, Inc. and Sanofi today announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis

Array BioPharma Inc. (Nasdaq: ARRY) announced today that it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada) to investigate the safety and efficacy of Array’s MEK inhibitor, binimetinib, with Merck’s anti-PD-1 therapy, KEYTRUDA

The Cambridge biotechnology company said Monday that it will make the largest donation ever of hemophilia drugs to developing nations, where the costs prevent thousands of people afflicted by the bleeding disorder from getting treatment